Wednesday, November 23, 2022 11:47:27 AM
Years ago Gilead bought a whole company just to acquire rights to a Hep C drug; a nuke. They hypothesized that another company was having good results in trials using 4 antivirals to treat Hep C. Gilead thought; lets combine the nuke with another competitors drug; an NS5a antiviral - Daclatasvir.
Gilead thought that the nuke and NS5a in combination could work as well as the other HCV pioneering partnership's treatment- Abbott (now Abbvie) and Enanta's. (that was about 2010 or 11)
Gilead paid about 11 billion for the compound and the reaction was similar to yours; it's too much money and it's not proven. I was in that final Phase 3 registration study in 2014 where Gilead was still proving dosing and duration in the middle of the decade. Conventional wisdom was that Gilead had lost it's mind and overpaid........ and was soon proven soundly incorrect.
In the case of Enanta, it was some unknown tiny company, but it did what JNJ, Merck, BMY, Roche, Sherring-Plough, Boehringer Ingelheim, et al couldn't do.
AND Enanta did it twice, in two successful launches of Hep C treatments.
There was a time that conventional wisdom said that a "nuke was necessary" to treat Hep C. And yet this small company in a partnership w/ Abbvie created a pan-genotypic Hep C 2 drug treatment with protease inhibitors they created in each - without the use of a nuke.
How many companies tried to create a Covid antiviral? Who will have the best? That same small company seems to have some of the best data I've seen. Yes, it's still early and things are not yet proven to your satisfaction. We won't have that long to wait for data.
Enanta has demonstrated *proficiency* with protease inhibitors with great success in the past.
Recent ENTA News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:20:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:18:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:17:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:14:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:05:29 PM
- Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference • Business Wire • 03/03/2026 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/23/2026 05:15:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:31:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:29:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:28:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:27:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/11/2026 09:43:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 09:00:44 PM
- Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting • Business Wire • 02/10/2026 12:00:00 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 • Business Wire • 02/09/2026 09:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2026 09:10:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2026 09:05:32 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 01/20/2026 09:42:25 PM
- Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook • Business Wire • 01/08/2026 12:00:00 PM
- Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference • Business Wire • 01/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2025 11:47:53 PM
Eco Science Solutions Integrates IDScan.net's DIVE Into Herbo Pay to Power Identity Verification, Compliance, and Fraud Prevention • ESSI • Mar 27, 2026 12:01 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
